6 days Ago By Defense World Staff
Wellington Management Group LLP purchased a new stake in Doximity, Inc. ( NASDAQ:DOCS – Free Report ) in the fourth quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor purchased 6,656 shares of the company’s stock, valued at approximately $355,000.
Other large investors also recently made changes to their positions in the company. QSV Equity Investors LLC lifted its position in shares of Doximity by 0.3% during the 4th quarter.
QSV Equity Investors LLC now owns 60,763 shares of the company’s stock valued at $3,244,000 after buying an additional 186 shares during the last quarter. Handelsbanken Fonder AB boosted its position in shares of Doximity by 0.7% in the fourth quarter.
Handelsbanken Fonder AB now owns 29,700 shares of the company’s stock valued at $1,586,000 after acquiring an additional 200 shares during the period. UMB Bank n.a.
grew its position in shares of Doximity by 69.1% during the 4th quarter. UMB Bank n.
a. now owns 575 shares of the company’s stock valued at $31,000 after purchasing an additional 235 shares in the last quarter. Fielder Capital Group LLC increased its stake in Doximity by 4.
5% in the 4th quarter. Fielder Capital Group LLC now owns 5,488 shares of the company’s stock worth $293,000 after acquiring an additional 235 shares during the last quarter. Finally, Larson Financial Group LLC increased its position in shares of Doximity by 49.
4% in the fourth quarter. Larson Financial Group LLC now owns 756 shares of the company’s stock worth $40,000 after purchasing an additional 250 shares during the last quarter. 87.
19% of the stock is owned by institutional investors. Analysts Set New Price Targets A number of research firms have weighed in on DOCS. Piper Sandler upgraded Doximity from a “neutral” rating to an “overweight” rating and raised their price target for the company from $31.
00 to $78.00 in a research report on Friday, February 7th. The Goldman Sachs Group increased their price target on shares of Doximity from $58.
00 to $80.00 and gave the company a “neutral” rating in a research report on Monday, February 10th. Stephens initiated coverage on Doximity in a research report on Friday, December 20th.
They issued an “equal weight” rating and a $55.00 price objective on the stock. Mizuho lifted their target price on shares of Doximity from $55.
00 to $65.00 and gave the company a “neutral” rating in a research note on Monday, February 10th. Finally, Leerink Partners raised Doximity from a “market perform” rating to an “outperform” rating and upped their price target for the stock from $60.
00 to $90.00 in a research note on Friday, February 7th. Eleven research analysts have rated the stock with a hold rating, eight have assigned a buy rating and two have assigned a strong buy rating to the company.
According to MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and a consensus target price of $64.72. Insider Activity In other news, Director Timothy S.
Cabral sold 20,000 shares of the company’s stock in a transaction dated Monday, February 3rd. The shares were sold at an average price of $57.62, for a total transaction of $1,152,400.
00. Following the completion of the sale, the director now owns 6,360 shares of the company’s stock, valued at $366,463.20.
This represents a 75.87 % decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link .
Insiders own 37.40% of the company’s stock. Doximity Stock Down 0.
4 % Shares of DOCS stock opened at $52.65 on Tuesday. Doximity, Inc.
has a 52 week low of $22.96 and a 52 week high of $85.21.
The firm has a market capitalization of $9.83 billion, a PE ratio of 52.65, a P/E/G ratio of 4.
10 and a beta of 1.41. The company has a 50 day moving average price of $64.
63 and a 200-day moving average price of $55.65. Doximity Profile ( Free Report ) Doximity, Inc operates a cloud-based digital platform for medical professionals in the United States.
The company's platform provides its members with tools built for medical professionals, enabling them to collaborate with their colleagues, coordinate patient care, conduct virtual patient visits, stay up to date with the latest medical news and research, and manage their careers. Recommended Stories Five stocks we like better than Doximity How to Invest in Biotech Stocks Why NVIDIA Stock Could Soar Despite Wall Street Downgrades Growth Stocks: What They Are, Examples and How to Invest Top 3 Large Cap Stocks Insiders Bought in Q1: Buy, Sell, or Hold Profitably Trade Stocks at 52-Week Highs 3 Hot New IPOs Defying the 2025 Market Slump Receive News & Ratings for Doximity Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Doximity and related companies with MarketBeat.com's FREE daily email newsletter .
.
